Opinion|Videos|January 28, 2025

Overview of the inMIND Study

Panelists discuss the inMIND study, exploring the efficacy and safety of mindetuximab for the treatment of relapsed or refractory non-Hodgkin lymphoma and its potential impact on future therapeutic strategies.


Latest CME